Enliven Therapeutics, Inc. (ELVN) Market Cap
Enliven Therapeutics, Inc. has a market capitalization of —.
No quote data available.
CEO: Richard A. Fair
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2020-03-12
Website: https://www.enliventherapeutics.com
Enliven Therapeutics, Inc. (ELVN) - Company Information
Market Cap: -|Sector: Healthcare
Company Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Analyst Sentiment
From 9 Active Polls
1Y Forecast: $67.00
▲ +0.0% Potential Upside
Consensus Target Metrics
Low Bound
$59
Median
$62
High Bound
$80
Average
$67
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
Sentiment volume allocation data unavailable.
Historical valuation matrix unavailable.
📘 Full Research Report
AI-Generated Research: This report is for informational purposes only.
Related Companies in Healthcare
📊 AI Financial Analysis
Powered by StockMarketInfo"Headline (2026-03-31, Q1): Revenue $0; Net income -$23.6M (EPS -$0.38). YoY (vs 2025-03-31): Net loss narrowed (from -$28.5M to -$23.6M), an improvement of ~17.2%, while EPS improved from -$0.57 to -$0.38. QoQ (vs 2025-12-31): Net loss also improved ~20.4% (from -$29.7M to -$23.6M). Margins: revenue-based margins were not meaningful as revenue was reported as $0; however, operating losses eased QoQ and YoY, consistent with some cost/interest offset improvements. Cash flow and balance sheet: Operating cash flow was -$19.3M in Q1 2026, improving vs -$15.8M in Q4 2025 (more negative QoQ), but still in line with persistent operating burn. The company ended the quarter with $132.2M cash and $320.2M short-term investments ($452.4M cash + ST investments), indicating strong liquidity. Net debt is negative (net cash position), with no meaningful debt load. Total equity was $453.4M, broadly stable/improving vs $459.6M in Q4 2025. Shareholder returns: Stock price closed at $48.11, up +199.4% over 1 year (>20% momentum), with no dividend and no disclosed buybacks in the provided cash flow. Valuation sentiment appears speculative/early-stage, supported by analyst targets around $59 (moderate upside vs $48). Revenue and Earnings-based metrics were not applicable for this analysis due to the company's pre-revenue status. The evaluation focused on cash runway, burn rate, and market sentiment instead."
Revenue Growth
Revenue was reported as $0 in all quarters provided, so no growth trajectory is observable.
Profitability
Net loss improved YoY (~17.2% less negative) and QoQ (~20.4% less negative). EPS improved from -$0.57 (2025-03-31) to -$0.38 (2026-03-31). Revenue-based margins were not meaningful due to $0 revenue.
Cash Flow Quality
Operating cash flow was -$19.3M (Q1 2026) vs -$15.8M (Q4 2025), indicating burn remains. No dividends; buybacks not evident in cash flow.
Leverage & Balance Sheet
Very low leverage: no meaningful debt; net debt is negative (net cash). Liquidity is strong with $452.4M cash + short-term investments and current ratio ~40.3x.
Shareholder Returns
Total return tailwind from strong market momentum: +199.4% 1y_change. Dividend = 0 and no repurchases shown, so appreciation is the driver.
Analyst Sentiment & Valuation
Consensus target is $59 vs $48.11 current (moderate upside). With heavy losses and pre-revenue operations, valuation likely depends on future commercialization rather than fundamentals.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.